{"entity":{"id":"nct07365241","kind":"trial","name":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer","aka":[],"tldr":"A phase 3 trial testing ABBV-706 in non-small-cell lung cancer, now recruiting.","summary":"A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer is a phase 3 interventional study registered as NCT07365241, led by AbbVie, and recruiting on the registry. Official title: A Phase 3 Randomised, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC). Planned enrolment is 531 participants (estimated). The study started in 2026-07-02 and primary completion is expected in 2030-09. No results have been posted on ClinicalTrials.gov.","status":"recruiting","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov NCT07365241","url":"https://clinicaltrials.gov/study/NCT07365241"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["abbv-706"],"companies":["abbvie"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07365241","phase":"3","setting":"A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 Versus Standard of Care in Subjects With Relapsed/Refractory Small Cell Lung Cancer (SCLC)","sponsor":"AbbVie","participation":[{"nct":"NCT07365241","source":"https://clinicaltrials.gov/study/NCT07365241","fetchedAt":"2026-10-07T16:55:42.201Z","studySha256":"53e84350e0ac71cd84cc2a18ecbbc251506a768c8d4e0db0e5c41c1ee5f88a8d","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-23","leadSponsor":"AbbVie","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":531,"enrolmentType":"ESTIMATED","siteCount":72,"recruitingSiteCount":72,"countries":["Austria","Belgium","Brazil","France","Germany","Greece","Japan","Spain","Switzerland","United States"]}],"started":"2026-07-02","startedType":"actual","enrolled":531,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07365241/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"abbv-706","kind":"drug","name":"ABBV-706","route":"/drugs/abbv-706/"},{"id":"amrubicin","kind":"drug","name":"Amrubicin","route":"/drugs/amrubicin/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}